Use of Donepezil for Treatment of Cocaine Dependence

This study has been completed.
Information provided by (Responsible Party):
Department of Veterans Affairs Identifier:
First received: April 27, 2007
Last updated: December 2, 2013
Last verified: November 2013

April 27, 2007
December 2, 2013
February 2007
September 2008   (final data collection date for primary outcome measure)
Cocaine safety in subjects receiving donepezil [ Time Frame: Two weeks ] [ Designated as safety issue: Yes ]
Patients will be evaluated for clinical and laboratory adverse events
The safety of cocaine administration in subjects receiving donepezil will be evaluated by electrocardiogram monitoring, self-reported adverse events, blood pressure, heart rate, 12-lead electrocardiograms, and safety laboratories. [ Time Frame: During dosing with intravenous cocaine, ECGs will be continuously monitored with a physician present. ]
Complete list of historical versions of study NCT00467389 on Archive Site
Cocaine pharmacokinetics and subjective effects [ Time Frame: 8 Hours ] [ Designated as safety issue: No ]
Plasma cocaine determined by mass spectrophotometry and subjective effects by VAS (visual analogue scale).
Plasma levels of cocaine and metabolites will be determined by liquid chromatography-tandem mass spectrometry after intravenous cocaine administration in placebo- and donepezil- treated subjects. Baseline and cocaine-induced increases in plasma HVA will [ Time Frame: Subjective effects of cocaine will be measured by VAS, BSCS, and the Multiple Choice Questionnaire. Additional psychometric measures will include the BSI, Beck Depression Inventory, POMS, and the Addiction Research Center Inventory. ]
Not Provided
Not Provided
Use of Donepezil for Treatment of Cocaine Dependence
Donepezil Effects on Cocaine Craving and Pharmacokinetics

The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.

This is a randomized, double-blind, double-dummy, placebo controlled, inpatient, single-center, parallel group evaluation of the potential for oral donepezil to attenuate cocaine-induced craving. Non-treatment-seeking cocaine-experienced volunteers will receive baseline treatment with intravenous cocaine (30Mg). Forty-two subjects that tolerate baseline cocaine infusions will then receive two subsequent intravenous doses of cocaine during double-blind treatment with oral placebo or 5 mg daily of donepezil. Each dose of cocaine will be preceded or followed by administration of intravenous placebo (saline) in a random order.

Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Cocaine Abuse and Dependence
Drug: Donepezil, 5 mg daily
This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
Other Name: Aricept
Experimental: Arm 1
Donepezil, 5 mg daily
Intervention: Drug: Donepezil, 5 mg daily
Grasing K, Mathur D, Newton TF, DeSouza C. Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug Alcohol Depend. 2010 Feb 1;107(1):69-75.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2008
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Non-treatment seeking, experienced cocaine users, who have used cocaine by smoking or intravenous injection within the four weeks prior to screening, and must supply a cocaine-positive urine obtained within four weeks of entry into the study.

Exclusion Criteria:

  • Shows signs of psychostimulant toxicity, or has a history of a medical adverse reaction to cocaine or other psychostimulants, including loss of consciousness, chest pain, cardiac ischemia, or seizure.
  • Has a current psychiatric disorder other than drug abuse or dependence or dementia.
  • Meets the DSM-IV criteria for dependence to opiates, benzodiazepines, alcohol, or other sedative-hypnotics.
  • Has received opiate-substitution therapy (methadone, LAAM, or buprenorphine) within two months prior to enrollment.
  • Has current or past history of seizure disorder, including alcohol- or psychostimulant- related seizures, or family history of seizure disorder.
  • Has a diagnosis of adult asthma, or chronic obstructive pulmonary disease, including a history of acute asthma within the past two years, and those with current or recent (with the past two years) treatment with an inhaled or oral beta-adrenergic agonist.
  • Has had head trauma that resulted in neurological sequelae.
  • Has an unstable medical condition, which, in the judgement of investigators, would make participation hazardous.
18 Years to 50 Years
Contact information is only displayed when the study is recruiting subjects
United States
Department of Veterans Affairs
Department of Veterans Affairs
Not Provided
Principal Investigator: Kenneth Grasing, MD Department of Veterans Affairs
Department of Veterans Affairs
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP